Andrew Thompson is CEO and co-founder of Proteus Digital Health, a California-based company building tiny ingestible sensors that can be incorporated into pills to let doctors know when patients take them. This is one of several connected products the company has in the pipeline that should help improve current diagnosis and treatment methods. Andrew was speaking at Wired Health on 29 April, 2014.
What we've created is a new category of therapeutic products. Today you have generic products, branded products and soon we'll have digital products". We're in an early phase of commercial release of these products and that will start to expand fairly dramatically over the next couple of years. We created an FDA De Novo device category for an ingestible sensor and we have permission to make use of that technology either as a co-ingested, co-packaged or encapsulated dose form. We've also created a new pathway for what I'm going to call a digital NDA [new drug approval], which could lead to a new class of therapeutic product. The first of these digital NDAs will start to appear in 2015. Andrew Thomson states, "What we've created is a new category of therapeutic products. Today you have generic products, branded products and soon we'll have digital products. And digital products are going to by far the most valuable and biggest category -- over time."
Video talk: https://www.youtube.com/watch?v=3aId6jSDSg0